ELCC 2023: Nivolumab + Chemotherapy Shows Continuous Benefit in NSCLC Versus Chemotherapy Alone
Three-year results from the CheckMate 816 study show event-free survival of 57 percent versus 43 percent with chemotherapy alone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.